Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.53 USD | +4.28% | -0.12% | +212.96% |
May. 15 | Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 74.45M |
---|---|---|---|---|---|
Net income 2022 | -45M | Net income 2023 | -35M | EV / Sales 2022 | - |
Net cash position 2022 | 123M | Net cash position 2023 | 106M | EV / Sales 2023 | - |
P/E ratio 2022 |
-2.13
x | P/E ratio 2023 |
-2.07
x | Employees | 10 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.88% |
1 day | +4.10% | ||
1 week | -4.02% | ||
Current month | +14.53% | ||
1 month | +83.30% | ||
3 months | +209.92% | ||
6 months | +219.69% | ||
Current year | +200.74% |
Managers | Title | Age | Since |
---|---|---|---|
Valerie Morisset
FOU | Founder | 55 | 18-10-17 |
Andrew Levin
CEO | Chief Executive Officer | 47 | 18-10-17 |
Emily Pimblett
AUD | Comptroller/Controller/Auditor | 40 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Liam Ratcliffe
BRD | Director/Board Member | 60 | 19-09-30 |
Adam Rosenberg
BRD | Director/Board Member | 54 | 20-09-30 |
Andrew Levin
CEO | Chief Executive Officer | 47 | 18-10-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 8.5 | +3.91% | 92 027 |
24-05-16 | 8.18 | +2.38% | 134,901 |
24-05-15 | 7.99 | -2.44% | 202,767 |
24-05-14 | 8.19 | -2.62% | 163,464 |
24-05-13 | 8.41 | -0.59% | 114,451 |
Delayed Quote Nasdaq, May 17, 2024 at 10:57 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+200.74% | 229M | |
+8.73% | 114B | |
+10.88% | 104B | |
-12.79% | 22.41B | |
-1.11% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.97% | 17.89B | |
+7.88% | 14.28B | |
+36.43% | 12.55B |
- Stock Market
- Equities
- ELYM Stock